Image (37366051 Ccb9 4ce6 9060 0d4fa9e00a66 01)
Enalapril Maleate
Product Images NDC 53002-2008
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Enalapril Maleate (NDC 53002-2008). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image (37366051 Ccb9 4ce6 9060 0d4fa9e00a66 02)
This seems to be a table displaying the incidence of various side effects in a clinical trial comparing the drug Enatapril to a placebo. The side effects are categorized by body system affected, and the table includes the number of patients who experienced each side effect in the Enatapril and placebo groups.*
Image (37366051 Ccb9 4ce6 9060 0d4fa9e00a66 03)
This text appears to be a dosage table for Creatinine based on different levels of renal function. The table provides information on the initial dosage of medication in milligrams per day, based on the clearance of creatinine and the individual's renal status. For normal renal function, the recommended initial dosage is 5mg per day, while for mild renal impairment it is also 5mg per day but for a clearance < 80mU/min. In moderate to severe impairment, the initial dose is 25mg per day for a clearance < 30mU/min. A dosage of 25mg per day is advised for dialysis patients on dialysis days. The table also contains a warning regarding anaphylactoid reactions during membrane exposure. The dosage on nondialysis days should be adjusted depending on the blood pressure response.*
Label Image (Lbl530022008)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
